ROCKVILLE, Md., March 9, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV Technology Platform, today announced it will present and hold a fireside chat at the Barclays Global Healthcare Conference on Wednesday, March 11, 2020, at 2:35 p.m. ET. The conference will be held in a virtual meeting format.
A live webcast of the presentation and fireside chat can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available in the Investors section of REGENXBIO's website for approximately 30 days following the presentation.
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.
Contacts:
Tricia Truehart
Investor Relations and Corporate Communications
347-926-7709
[email protected]
Investors:
Heather Savelle, 212-600-1902
[email protected]
Media:
David Rosen, 212-600-1902
[email protected]
SOURCE REGENXBIO Inc.
![](https://rt.prnewswire.com/rt.gif?NewsItemId=PH44033&Transmission_Id=202003090700PR_NEWS_USPR_____PH44033&DateId=20200309)
Share this article